2957 Dicker, Adam P. - Thomas Jefferson University - Thomas Jefferson University
axd121

Adam P. Dicker, MD, PhD

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 503-0013 fax

Most Recent Peer-reviewed Publications

  1. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
  2. Study of Unrecovered Strain and Critical Stresses in One-Way Shape Memory Nitinol
  3. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905
  4. High dose rate brachytherapy boost for prostate cancer: A systematic review
  5. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
  6. A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect
  7. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
  8. Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial
  9. The quality frontier
  10. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
  11. A model to predict deflection of bevel-tipped active needle advancing in soft tissue
  12. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
  13. The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging
  14. Polyacrylamide phantom for self-actuating needle-tissue interaction studies
  15. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: Report of the american society for radiation oncology cancer biology/radiation biology task force, executive summary
  16. Radiation therapy and the immune system: Learning to live together
  17. Epidermal growth factor receptor mutation status and Rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation
  18. Phase i trials involving radiation therapy, quantifying the risks
  19. Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: A meta-analysis
  20. Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008 : A population-based analysis
0